Ayala Pharmaceuticals, an Israeli clinical-stage company that develops medicines for cancers that are genetically defined, announced Tuesday it had closed a $30 million Series B funding round. The financing round was led by Swiss multinational pharmaceutical company Novartis, with participation from SBI JI Innovation Fund and existing investors Israel Biotech Fund, aMoon and Harel Insurance […]

Researchers from the Technion - Israel Institute of Technology have successfully treated a cancerous tumor with a synthetic cell that produces anti-cancer proteins within the tissue of the tumor.

Glioblastoma multiforme, also known as "The Terminator", is one of the deadliest cancers, but an "nano-bullet" has proven effective in treating, and potentially curing GBM.

A research team at the Technion has discovered two proteins that could be key in controlling the growth of cancer cells.

In the war on cancer, cyberwarfare may have some important insights in discovering a treatment that would tip the balance in favor of the immune system.